Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe first month of weight loss injections is a settling-in period, not a results period. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) begin at a low starter dose designed to let your body adjust — most people see modest changes in appetite and some early weight movement, rather than dramatic numbers. These are prescription-only medicines; a clinician assesses your suitability before anything is dispensed. Here is an honest account of what that opening month actually involves, and what it means for the decision you are trying to make.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear regularly is why the first pen feels underwhelming. The honest answer is that it is supposed to. Mounjaro starts at 2.5 mg and Wegovy at 0.25 mg, doses set by the medicine's licensed schedule specifically to reduce nausea and other gastrointestinal effects that come with starting a GLP-1 or dual GIP/GLP-1 medicine. Your digestive system slows down as gastric emptying is reduced, and rushing that process at full strength is what causes real discomfort.
Your prescriber will typically review progress before moving you up in four-week steps. That titration pattern matters because the therapeutic doses (the strengths that produced the trial results) are higher up the schedule. Expecting the 2.5 mg pen to deliver the same effect as 10 mg or 15 mg is the single most common misconception about month one, and it is one worth letting go early. The how weight loss injections work page covers the mechanism in more detail if you want to understand the biology before starting.
The NHS patient information for tirzepatide sets out this titration approach clearly, and it is worth reading before your first injection so the schedule does not come as a surprise. You can find it on the NHS tirzepatide medicine page.
Appetite is usually the first thing to shift. Many people notice they feel full sooner at meals, or that food is simply less compelling, within the first one to two weeks. That change is real and meaningful even if the scales have not moved much yet.
Weight loss in month one tends to be modest. Some of it is fluid; some reflects the calorie reduction that follows reduced appetite. Clinical trial data (from trials running 68 to 72 weeks) show averages that build cumulatively. Four weeks is a small fraction of that timeline. If you are curious about what the longer picture looks like, the three-month outcomes page gives a realistic sense of the trajectory most people follow.
Side effects in this period are almost entirely gastrointestinal: nausea (most common), constipation, looser stools, burping, and sometimes mild fatigue or headache. They are typically most noticeable in the days after a new dose and ease as the weeks pass. Eating smaller portions, avoiding fatty or very spicy food, and staying well hydrated all help. If side effects are severe or persistent, your prescribing clinician needs to know.
One practical point: if you are using Mounjaro, oral contraceptives may be less reliably absorbed during the first four weeks of treatment and for four weeks after each dose increase, because gastric emptying slows. NHS guidance recommends adding a non-oral method during those windows. Speak to your prescriber about this before your first injection.
Some people ask whether a single month is worth starting. It is a fair question. Clinically, one month gets you through the starter dose and gives you early data about tolerability and appetite response, but it does not give you a full picture of efficacy. The medicines are designed as sustained treatments alongside dietary changes and increased activity, not short courses. Some people also ask about how a once-a-month weight loss injection fits into a longer treatment plan, and that page is a useful starting point for understanding the dosing rhythm.
That said, the question of whether one month of treatment is clinically appropriate is one your prescriber will discuss with you. Stopping and restarting repeatedly, or treating a one-month supply as a trial run in isolation, is not how the licensed treatment schedule works. A clinician who knows your full picture is the right person to advise on duration.
For context on what private treatment involves in terms of cost, the weight loss injection pricing page explains what a transparent private price covers and what to look out for when comparing providers. It is useful reading before committing to anything.
If you want to understand how your GP fits into all of this, including whether NHS access might be relevant to your situation, the injections through a GP page covers the NHS eligibility criteria and current waiting-list reality clearly.
These are prescription-only medicines. The only legal route to them in the UK is a prescription following a proper clinical assessment, identity verified, weight confirmed, medical history reviewed by a qualified prescriber. At nume, that review is carried out personally by a GPhC-registered Independent Prescriber, not by an algorithm, on the same day your consultation is submitted.
The MHRA has documented counterfeit weight-loss pens entering the UK through social media and unregistered sellers, some containing harmful substances. Any seller offering these medicines without a clinical assessment is a red flag regardless of price. You can verify any UK online pharmacy on the GPhC pharmacy register, it takes thirty seconds and it matters.
If you are ready to find out whether treatment is suitable for you, you can check your eligibility with a free consultation. There is no obligation, and the clinical team will give you an honest answer about whether this is right for your situation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.